摘要
目的比较门冬胰岛素30与精蛋白生物合成人胰岛素30R（以下简称人胰岛素30R）治疗2型糖尿病的疗效。方法50例2型糖尿病患者随机分为门冬胰岛素30组与人胰岛素30R组各25例，采用每日早晚皮下注射门冬胰岛索30与人胰岛素30R，进行为期12周的观察。比较8、12周后两组7个时点血糖、12周后糖化血红蛋白（HbAlc）、低血糖事件的差异。结果门冬胰岛素30组与人胰岛素30R组治疗后血糖、HbAlc较治疗前均明显下降（P〈0．01），门冬胰岛素30组餐前、餐后2h血糖低于人胰岛素30R组，差异有统计学意义（P〈0．05），门冬胰岛素30组低血糖发生次数低于人胰岛素30R组，但差异无统计学意义（P〉0．05）。结论对于2型糖尿病患者，2次／d注射门冬胰岛素30较人胰岛素30R对餐后2h血糖控制更有效，减少低血糖风险，为患者提供更灵活的用餐时间。
Objective To compare the efeet and safety between premixed insulin aspart 30 and Isophane protamine biosynthetic human insulin （Human insulin premix 30R）in the patients with type 2 diabetes. Methods 50 type 2 diabetes patients were randomly recruited and hospitalized with 25 patients on biphasic Insulin aspart（NovoMixR30）and 25 patients on Human insulin premix 30R subcutaneous injected before breakfast and dinner. To compare the blood sugar after 8 weeks and 12 weeks treated and the glycosylated hemoglobin （HbAlc）and hypoglycemic episodes after 12 weeks treated. Results Blood sugar and HbAlc levels of patients in NovoMixR30 and Human Insulin Premix 30R groups were significantly lower than protreat（P〈0.01）. Blood sugar of Before meal and after 2 hours meal in the NovoMixR30 group patients were significantly lower than those in the Human Insulin Premix 30R group pat/ents（P〈0.05）. Hypoglyeemic episodes in the NovoMixR30 group patients were lower than those in the Human Insulin Premix 30R group patients,but no significant（P〉0.05）. Conclusion Twiee---dialy injection of NovoMixR30 might be able to control better hlcod sugar of before and after 2 hours meal and reduce hypoglyeemic risk. And patients might be more convenient to eat.
